News

Berlin Authority published a case law regarding the DPO requirements and the risk of conflict of interest due to the dual position of DPO.


In this case the person was simultaneously the managing director of two service companies that processed personal data on behalf of the company for which he was acting as also data protection officer. These service companies are also part of the group; they provide customer service and execute orders.

Arecor Therapeutics plc

(“Arecor”, the “Company” or the “Group”)


HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DEMONSTRATE SIGNIFICANTLY ACCELERATED INSULIN ABSORPTION AND EARLY EXPOSURE COMPARED TO GOLD STANDARD INSULINS NOVOLOG® AND FIASP®

For 2022 only the Oncology Conference and the Precision Medicine Conference will both run in conjunction with each other. Join Bionow, expert speakers and industry colleagues to discuss the current oncology landscape and the future of precision medicine.

DIVERSA is your One Nucleus member expert in drug delivery systems and pharmaceutical technology. DIVERSA is a spin-off of the Health Research Institute of Santiago de Compostela (IDIS) and the Servizo Galego de Saúde (SERGAS) established in January 2022. We have a global vocation to enable innovative therapies get to the clinic and the patients.


In line with its internationalization efforts, DIVERSA has been selected under the ICEX NEXT program on a competitive basis amongst more than 150 Spanish SMEs. There are two main reasons, we have been granted this chance:

Charles River Avian products, which are used for virus research and to produce veterinary and human vaccines, are now available through the BioIVT Digital Portal

• Two new companies, Neobe Therapeutics and Genenet Technology, have been awarded space in the Lab Hotel

• The Lab Hotel provides free laboratory and office accommodation for start-up companies for six months

• Companies in the Lab Hotel have access to scientific and business support while they develop their innovations and secure their next round of funding.





 


●  BioMed Realty and Babraham Research Campus Ltd to deliver 40,000 square foot building through a new joint venture


●  This development represents BioMed’s investment in its third building on the Campus and provides much needed space for scale-ups in the Cambridge, UK market 

Pages